Trial of Combined Radiotherapy and Vertebroplasty for Patients With Painful Metastatic Spinal Lesions
Phase 2
Recruiting
- Conditions
- Spinal Metastases
- Interventions
- Radiation: RadiotherapyProcedure: Vertebropladty
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 64
- Registration Number
- NCT04242589
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
A Nutritional Supplement to Support People With Non-small Cell Lung Cancer
Not Applicable
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Other: PlaceboDietary Supplement: Nutritional supplement
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 60
- Registration Number
- NCT04175769
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
Phase 2
Withdrawn
- Conditions
- Metastatic Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- AHS Cancer Control Alberta
- Registration Number
- NCT04149444
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma
Phase 2
Completed
- Conditions
- SCCHN
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 6
- Registration Number
- NCT04107103
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT)
Not Applicable
Recruiting
- Conditions
- Squamous Cell Carcinoma of the Oropharynx
- Interventions
- Radiation: De-intensified chemoradiotherapy
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 32
- Registration Number
- NCT04104945
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting
Phase 2
- Conditions
- Breast Cancer
- Interventions
- Dietary Supplement: Docosahexaenoic acid (DHA)Drug: Placebo oral capsule
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 52
- Registration Number
- NCT03831178
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy
Phase 2
Active, not recruiting
- Conditions
- Squamous Cell Carcinoma of the Skin
- Interventions
- Combination Product: Avelumab and Radical radiotherapy
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 20
- Registration Number
- NCT03737721
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Alberta, Canada
Unilateral Neck Radiotherapy in Head and Neck Cancer
Not Applicable
Recruiting
- Conditions
- Head and Neck Neoplasms
- Interventions
- Radiation: Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck)Radiation: Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck)
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 175
- Registration Number
- NCT03622164
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
The Breast Cancer & Physical Activity Level (BC-PAL) Pilot Study
Not Applicable
Completed
- Conditions
- Breast Cancer Survivorship
- Interventions
- Behavioral: Higher intensity physical activity interventionBehavioral: Lighter intensity physical activity intervention
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 45
- Registration Number
- NCT03564899
- Locations
- 🇨🇦
The Rehabilitation, Exercise and Complementary (REACH) center within the Holy Cross Center, Calgary, Alberta, Canada
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 18
- Registration Number
- NCT03469011
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
© Copyright 2025. All Rights Reserved by MedPath